Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Related AGN
Will The New Pfizer Be A Winner? SunTrust Analyst Thinks So, Upgrades Stock
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Stocks Edge Higher In Pre-Thanksgiving Trade; Pfizer Leads Dow (Investor's Business Daily)
Related VRX
Early Global News: Russia Denis Airspace Violation, Ackman Boosts Stake In Valeant, And German Company That's A Huge Threat To Tesla
The Valeant News No One Is Talking About
Skin Disease Drug Costs Jump (Investor's Business Daily)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General


Related Articles (AGN + VRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters